CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial

Andreas Mackensen, John B.A.G. Haanen, Christian Koenecke, Winfried Alsdorf, Eva Wagner-Drouet, Peter Borchmann, Daniel Heudobler, Barbara Ferstl, Sebastian Klobuch, Carsten Bokemeyer, Alexander Desuki, Florian Lüke, Nadine Kutsch, Fabian Müller, Eveline Smit, Peter Hillemanns, Panagiotis Karagiannis, Erol Wiegert, Ying He, Thang HoQing Kang-Fortner, Anna Melissa Schlitter, Catrine Schulz-Eying, Andrew Finlayson, Carina Flemmig, Klaus Kühlcke, Liane Preußner, Benjamin Rengstl, Özlem Türeci, Uğur Şahin*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

30 Citations (Scopus)
4 Downloads (Pure)


The oncofetal antigen Claudin 6 (CLDN6) is highly and specifically expressed in many solid tumors, and could be a promising treatment target. We report dose escalation results from the ongoing phase 1/2 BNT211-01 trial evaluating the safety and feasibility of chimeric antigen receptor (CAR) T cells targeting the CLDN6 with or without a CAR-T cell-amplifying RNA vaccine (CARVac) at two dose levels (DLs) in relapsed/refractory CLDN6-positive solid tumors. The primary endpoints were safety and tolerability, maximum tolerated dose and recommended phase 2 dose (RP2D). Secondary endpoints included objective response rate (ORR) and disease control rate. We observed manageable toxicity, with 10 out of 22 patients (46%) experiencing cytokine release syndrome including one grade 3 event and 1 out of 22 (5%) with grade 1 immune effector cell-associated neurotoxicity syndrome. Dose-limiting toxicities occurred in two patients at the higher DL, resolving without sequelae. CAR-T cell engraftment was robust, and the addition of CARVac was well tolerated. The unconfirmed ORR in 21 evaluable patients was 33% (7 of 21), including one complete response. The disease control rate was 67% (14 of 21), with stable disease in seven patients. Patients with germ cell tumors treated at the higher DL exhibited the highest response rate (ORR 57% (4 of 7)). The maximum tolerated dose and RP2D were not established as the trial has been amended to utilize an automated manufacturing process. A repeat of the dose escalation is ongoing and will identify a RP2D for pivotal trials. Identifier: NCT04503278 .

Original languageEnglish
Pages (from-to)2844-2853
Number of pages10
JournalNature Medicine
Issue number11
Publication statusPublished - 23 Nov 2023

Bibliographical note

Publisher Copyright: © 2023, The Author(s).


Dive into the research topics of 'CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial'. Together they form a unique fingerprint.

Cite this